Dr. Jeff Karp, a chemical engineer, is a world-leader in the fields of drug delivery, stem cell therapeutics, and tissue adhesives. He is an associate professor at Brigham and Women’s Hospital and Harvard Medical School, principal faculty at the Harvard Stem Cell Institute, and an affiliate faculty at the Broad Institute and at the Harvard-MIT Division of Health Sciences and Technology.
He has published 100 peer-reviewed papers (with over 10,000 citations), has given 210 national and international invited lectures, and has 65 issued or pending patents. Several technologies developed in his lab have formed the foundation for multiple products on the market and currently under development and for the launch of four companies, including Gecko Biomedical, Skintifique, Frequency Therapeutics, and Alivio Therapeutics.
The Boston Business Journal recognized him as a champion in health care innovation, and MIT’s Technology Review Magazine (TR35) also recognized Dr. Karp as one of the "top innovators in the world" (three members from his laboratory have received this award).
His work has been selected by Popular Mechanic’s “Top 20 New Biotech Breakthroughs that Will Change Medicine.” He gave a TEDMED talk on bioinspired medical innovation and is a member of the TEDMED editorial advisory board. In 2015, he received a Breakthrough Award from the Kenneth Rainin Foundation and was a commencement speaker at the University of Toronto.
Dr. Karp was selected as the outstanding faculty undergraduate mentor among all faculty at MIT, and he received the HST McMahon Mentoring award for being the top mentor of Harvard-MIT students. To date, 17 trainees from his laboratory have secured faculty positions.